BMC Cardiovasc Disord
November 2022
Introduction: Congenital heart disease (CHD) is one of the most prevalent birth defects in the world. The pathogenesis of CHD is complex and unclear. With the development of metabolomics technology, variations in metabolites may provide new clues about the causes of CHD and may serve as a biomarker during pregnancy.
View Article and Find Full Text PDFA series of dinuclear compounds of [Ru(bpy)(2)(tpphz)Ln(TTA)(3)](PF(6))(2) (tpphz = tetrapyrido[3,2-a:2',3'-c:3'',2''-h:3''',4'''-j]phenazine; Ln = Er(III), Nd(III), Yb(III) and Gd(III); TTA = 2-thenoyltrifluoroacetone) have been prepared by attachment of a [Ln(TTA)(3)] fragment at the vacant diimine site of the luminescent mononuclear complex [Ru(bpy)(2)(tpphz)](PF(6))(2). In the solid state, in CH(2)Cl(2) solution and in Tris-HCl buffer solution of these dinuclear complexes Ru-Ln, sensitized near-infrared (NIR) luminescence is observed from Nd and Yb centres following excitation of the d-block unit, which results from the effective Ru → Ln (Ln = Nd, Yb) energy transfer, but no Er-based NIR luminescence is produced. The (3)MLCT (MLCT = metal to ligand charge transfer) emission is partly quenched in the Ru-Nd complex, slightly increased in the Ru-Yb complex, and is not changed in the Ru-Ercomplex.
View Article and Find Full Text PDFMononuclear ruthenium complex 1 and dinuclear complex 2 were synthesized by reaction of the appropriate bidentate pyrazolyl-pyridyl-based ligand L (L = 1,4-bis(3-(2-pyridyl)pyrazol-1-ylmethyl)benzene) with cis-Ru(bipy)(2)Cl(2)·2H(2)O. They were characterized by elemental analyses, ESI-MS, (1)H spectroscopy, and X-ray crystallography for 2. Compounds 1 and 2 both emit strongly in solid states and in solutions at 298 K with the lifetimes in the microsecond range.
View Article and Find Full Text PDF